High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma (HITT)
This study is currently recruiting participants.
Verified April 2013 by Lund University Hospital
Sponsor:
Lund University Hospital
Collaborator:
Bayer
Information provided by (Responsible Party):
Lund University Hospital
ClinicalTrials.gov Identifier:
NCT00761384
First received: September 26, 2008
Last updated: April 19, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | No date given |
| Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |